{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:51:43Z","timestamp":1786992703073,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["218407"],"award-info":[{"award-number":["218407"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jinf.2025.106510","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T19:36:28Z","timestamp":1747683388000},"page":"106510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study"],"prefix":"10.1016","volume":"91","author":[{"given":"Judith","family":"Breuer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-8067","authenticated-orcid":false,"given":"Jennifer","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Aylott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4924-4810","authenticated-orcid":false,"given":"Helen J.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McKie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-0853","authenticated-orcid":false,"given":"William","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-327X","authenticated-orcid":false,"given":"Kim","family":"Gemzoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain A.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bethune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-2821","authenticated-orcid":false,"given":"Jonathan","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7205-8947","authenticated-orcid":false,"given":"Michael","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4681-9586","authenticated-orcid":false,"given":"Julianne R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Marina Martin","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-7800","authenticated-orcid":false,"given":"Laura","family":"Buggiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-8330","authenticated-orcid":false,"given":"Effrossyni","family":"Gkrania-Klotsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-7095","authenticated-orcid":false,"given":"Ewan","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3427-3734","authenticated-orcid":false,"given":"Charles","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Skingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-2375","authenticated-orcid":false,"given":"David M.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"#cr-split#-10.1016\/j.jinf.2025.106510_bib1.1","unstructured":"World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic"},{"key":"#cr-split#-10.1016\/j.jinf.2025.106510_bib1.2","unstructured":"2023. Available at: https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic. Accessed December 12, 2024."},{"key":"10.1016\/j.jinf.2025.106510_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/cid\/ciab438","article-title":"The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data","volume":"74","author":"Chodick","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021","volume":"70","author":"Embi","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2025.106510_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jinf.2021.12.035","article-title":"Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: a systematic literature review and meta-analysis","volume":"84","author":"Marra","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2025.106510_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.jinf.2025.106510_bib6","doi-asserted-by":"crossref","first-page":"n2244","DOI":"10.1136\/bmj.n2244","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jinf.2025.106510_bib7","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/cid\/ciaa1166","article-title":"Household transmission of severe acute respiratory syndrome coronavirus-2 in the United States","volume":"73","author":"Lewis","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jinf.2025.106510_bib9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s12879-021-06429-5","article-title":"Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report","volume":"21","author":"Niyonkuru","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.jinf.2025.106510_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jinf.2025.106510_bib12","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2025.106510_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.2022.2832","article-title":"Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial","volume":"327","author":"Gupta","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2025.106510_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2022.08.021","article-title":"Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion","volume":"29","author":"Andr\u00e9s","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2025.106510_bib15","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1093\/cid\/ciac601","article-title":"Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 Omicron variant","volume":"76","author":"Huygens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00266-23","article-title":"Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving sotrovimab","volume":"67","author":"Palomino-Cabrera","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2025.106510_bib17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2025.106510_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cmi.2022.05.002","article-title":"Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab","volume":"28","author":"Vellas","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2025.106510_bib19","unstructured":"UK Department of Health & Social Care. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. Available at: \u3008https:\/\/www.gov.uk\/government\/publications\/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report\/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies#recommendations\u3009. Accessed December 12, 2024."},{"key":"10.1016\/j.jinf.2025.106510_bib20","unstructured":"NHS England. Commissioning Framework: COVID-19 Therapeutics for Non-Hospitalised Patients. Updated 29 March 2023. Available at: https:\/\/www.england.nhs.uk\/coronavirus\/publication\/commissioning-framework-covid-19-therapeutics-for-non-hospitalised-patients\/. Accessed April 29, 2025."},{"key":"10.1016\/j.jinf.2025.106510_bib21","unstructured":"European Medicines Agency. Xevudy. Summary of Product Characteristics 2023. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xevudy\u3009. Accessed December 12, 2024."},{"key":"10.1016\/j.jinf.2025.106510_bib22","article-title":"Resistance analysis in the COMET-TAIL study: participants with mild-to-moderate COVID-19 treated with intramuscular or intravenous sotrovimab","volume":"9","author":"Moya","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fvl-2023-0146","article-title":"Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study","volume":"18","author":"Subramanian","year":"2023","journal-title":"Future Virol"},{"key":"10.1016\/j.jinf.2025.106510_bib24","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2025.106510_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.2024.1014","article-title":"When it comes to SARS-CoV-2 clearance, people who are immunocompromised are not all alike","volume":"331","author":"Rubin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2025.106510_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1126\/science.adc9127","article-title":"Imprinted antibody responses against SARS-CoV-2 Omicron sublineages","volume":"378","author":"Park","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jinf.2025.106510_bib27","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","article-title":"Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains","volume":"13","author":"Case","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jinf.2025.106510_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jinf.2025.106510_bib29","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(22)01938-9","article-title":"WHO's therapeutics and COVID-19 living guideline on mAbs needs to be reassessed","volume":"400","author":"Wu","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2025.106510_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ccell.2023.04.005","article-title":"Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer","volume":"41","author":"Wu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jinf.2025.106510_bib31","article-title":"Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England","volume":"17","author":"Harman","year":"2023","journal-title":"Influenza Other Respir Virus"},{"key":"10.1016\/j.jinf.2025.106510_bib32","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s12879-024-09311-2","article-title":"Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England","volume":"24","author":"Patel","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2025.106510_bib33","article-title":"Effectiveness of sotrovimab and molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform","author":"Tazare","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.jinf.2025.106510_bib34","article-title":"Comparative effectiveness of nirmatrelvir\/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform","volume":"34","author":"Zheng","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jinf.2025.106510_bib35","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s15010-024-02245-6","article-title":"Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review","volume":"52","author":"Drysdale","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2025.106510_bib36","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10875-023-01504-9","article-title":"Persistent SARS-CoV-2 PCR positivity despite anti-viral treatment in immunodeficient patients","volume":"43","author":"Chan","year":"2023","journal-title":"J Clin Immunol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:08:23Z","timestamp":1785330503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0163445325001045"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106510","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106510"}}